DE3213139A1 - Compositions which dissolve urinary calculi - Google Patents

Compositions which dissolve urinary calculi

Info

Publication number
DE3213139A1
DE3213139A1 DE19823213139 DE3213139A DE3213139A1 DE 3213139 A1 DE3213139 A1 DE 3213139A1 DE 19823213139 DE19823213139 DE 19823213139 DE 3213139 A DE3213139 A DE 3213139A DE 3213139 A1 DE3213139 A1 DE 3213139A1
Authority
DE
Germany
Prior art keywords
iron
aluminum
acid
complexing
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19823213139
Other languages
German (de)
Inventor
Des Erfinders Auf Nennung Verzicht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LESKOVAR PETER DR ING
Original Assignee
LESKOVAR PETER DR ING
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19803046580 external-priority patent/DE3046580A1/en
Application filed by LESKOVAR PETER DR ING filed Critical LESKOVAR PETER DR ING
Priority to DE19823213139 priority Critical patent/DE3213139A1/en
Publication of DE3213139A1 publication Critical patent/DE3213139A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of certain carboxylic acids or carboxylic acid derivatives which have a litholytic action, according to Patent ... (Patent Application P 3046580.6), or the salts thereof together with calcium- and oxalate-complexing compounds is described.

Description

Die vorliegende Erfindung betrifft eine weitere Ausbildung der in der Patentanmeldung P 3< > **6 580.6 beschriebenen harnsteinauflösenden Mittel.The present invention relates to a further embodiment of the patent application P 3 < > ** 6 580.6 described urinary stone dissolving agents.

Aus der Patentanmeldung P 3° 46 580.6 ist bekannt, daß bestimmte Carbonsäuren oder Carbonsäurederivate bzw. Älhre Salze als kalziumbindende Mittel zur Pro- bzw. Metaphylaxe von Harnsteinen eingesetzt werden können.From the patent application P 3 ° 46 580.6 it is known that certain carboxylic acids or carboxylic acid derivatives or Ä Their salts may be employed as calcium-binding agents for process or metaphylaxis of urinary stones.

Überraschenderweise hat sich nunmehr herausgestellt, daß sowohl Kalziumoxalat als auch -phosphatsteine zum Teil mit Anfangsgewichten bis über 600 mg dann bevorzugt auflösen lassen, wenn die in der Hauptanmeldung erwähnten Verbindungen zusätzlich mit stark kalziumkomplexierenden und oxalatkomplexierenden Verbindungen gegeben werden. j Als kalziumkomplexierende Verbindungen sind insbesondere (DL-2,3-Butylendinitrilo)-tetraessigsäure, (1,2-Diphenyläthylendinitrilo)-tetraessigsäure,(trans-Cyclopentylendinitxj tetraessigsäure, 1,2,3-Tris-(N,N-bis(carboxymethyl)amino)-propan, (1-PhenyläthylendinitriIo)-tetraessigsäure, Triäthylentetraminhexaessigsäure, Tetraäthylenpentaaminohqtaessigsäure und trans-Diaminocyclohexan-Ν,Ν,Ν1,N'-tetraessigsäure eingesetzt werden, und zwar vorzugsweise als Alkalisalze oder als Magnesium-, Aluminium-, Eiseno.der Zinksalze. Besonders vorteilhaft sind bei allen Komplexonen Natrium- Kalium- Magnesiumsalze, bei dem die Kationen in ihrem stöchiometrischen erhältnis entsprechend den Verhältnissen im Blutserum vorliegen. Aus physiologischen Überlegungen sind auch die Natriura-Surprisingly, it has now been found that both calcium oxalate and calcium phosphate stones, in some cases with initial weights of over 600 mg, can be dissolved preferentially when the compounds mentioned in the main application are given in addition with highly calcium-complexing and oxalate-complexing compounds. Calcium-complexing compounds are in particular (DL-2,3-butylenedinitrilo) tetraacetic acid, (1,2-diphenylethylenedinitrilo) tetraacetic acid, (trans-cyclopentylenedinitxj tetraacetic acid, 1,2,3-tris- (N, N-bis (carboxymethyl ) amino) propane, (1-phenylethylenedinitriIo) -tetraacetic acid, triethylenetetraminehexaacetic acid, tetraäthylenpentaaminohqtaacetic acid and trans-diaminocyclohexane-Ν, Ν, Ν 1 , N'-tetraacetic acid, aluminum, aluminum, or magnesium salts are used Of the zinc salts. Sodium, potassium and magnesium salts are particularly advantageous for all complexones, in which the cations are present in their stoichiometric ratio in accordance with the proportions in the blood serum.

BAD ORIGINALBATH ORIGINAL

Kalium- Magnesium- Kalziumsalze von Vorteil, da hier die Kationen den Serumkationen entsprechen. Das Vorhandensein des Kalziums im Molekül stört nicht, da im Harn eine fast doppelt so hohe Kalziumkonzentration als im Serum vorliegt und es außerdem an Hand der günstigeren Komple::konstante zum Magnesium- Kalzium-Austausch in den Natrium-Kalium-Magnesium-Kalziumkomplexonen kommt.Potassium, magnesium and calcium salts are beneficial here the cations correspond to the serum cations. The presence of calcium in the molecule does not interfere, since the calcium concentration in the urine is almost twice as high as in the serum and it is also based on the cheaper complex :: constant for magnesium-calcium exchange comes in the sodium-potassium-magnesium-calcium complexes.

Als oxalntkoraplexierende Spüllösungen können wasserlöslich physiologisch unbedenkliche Salze von Aluminium, Eisen, Lanthan, Neodym, Niob, Yttrium, Ytterbium, Cer, Neptunium, Samarium, Gadolinium, Zink, Mangan, Lutetium, Magnesium oder Strontium verwendet werden. Vorzugsweise werden Aluminium-Laktat, Aluminium-Citrat, Aluminium-Nitrat, Aluminium-Sulfat, Eisen-Citrat, Eisen-Kaliuracitrat, Eisen-Ammpniumcitrat, Eisen-Glukonat, Eisen-Laktat, Eisensalze der Glukose, Niob-Nitrat oder Lanthan-Nitrat verwendet.As oxaline-coraplexing rinsing solutions can be water-soluble physiologically harmless salts of aluminum, iron, lanthanum, neodymium, niobium, yttrium, ytterbium, cerium, neptunium, Samarium, gadolinium, zinc, manganese, lutetium, magnesium or strontium can be used. Preferably be Aluminum lactate, aluminum citrate, aluminum nitrate, aluminum sulfate, iron citrate, iron potassium uracitrate, Iron ammonium citrate, iron gluconate, iron lactate, Iron salts of glucose, niobium nitrate or lanthanum nitrate are used.

Zusätzlich zu diesen Verbindungen können zur Lockerung der organischen Steinroatrix auch Gallensäuren und Lezithin und als Kristallisationsheinmer auch Chondroitinsulfat und Natiium-Pyrophosphat bzw. Natrium-Polyphogphat eingesetzt werden.In addition to these compounds, bile acids and bile acids can also be used to loosen the organic stone matrix Lecithin and, as a crystallization inhibitor, also chondroitin sulfate and sodium pyrophosphate or sodium polyphosphate can be used.

Die kalzium- und oxalatkomplexierenden bzw. -bindenden Verbindungen werden in Mengen von 0,01 - 0,25 molar eingesetzt, wobei bei in vitro-Versuchen noch Erfolge mit 0,001 molaren Lösungen erzielt werden konnten. Insbesonde der Bereich zwischen 0,01 - 0,25 molar hat sich als günst erwiesen. Bei Substanzen ohne definiertes Molekulargewich wie beispielsweise Polyphosphaten ergibt sich ein Einsatzbereich von etwa 0,01 - 2o9i. Die zur Auflockerung der organischen Steinmatrix eingesetzten Gallensäuren werden in einer Geaamtkonzentration von etwa 5 g imThe calcium and oxalate complexing or binding compounds are in amounts of 0.01-0.25 molar used, whereby in in vitro tests it was still possible to achieve successes with 0.001 molar solutions. In particular the range between 0.01 and 0.25 molar has proven to be favorable. For substances without a defined molecular weight such as polyphosphates, a range of use of about 0.01-2o9i results. The one to loosen up The bile acids used in the organic stone matrix are in a total concentration of about 5 g im

BAD ORIGINALBATH ORIGINAL

Bereich von 0,1 - 20,0 g/l eingesetzt; bei Lezithin wird eine gesättigte bzw. bei Raumtemperatur nach mehrstündiger Äquilibrierung erzielte Gleichgewichtskonzentration verwendet. Range from 0.1 - 20.0 g / l used; lecithin becomes saturated or at room temperature equilibrium concentration achieved after several hours of equilibration is used.

Die erfindungsgemäß eingesetzten Lösungen können weiterhin zum Schutz des Urothels bestimmte makromolekulare Stoffe enthalten wie beispielsweise Albumin, Polyvinylpyrrolidon, Dextran, Polyvinylacetat, Polyvinylalkohol. Äthylenglykole mit einem mittleren j Molekulargewicht zwischen 2ooo - 4ooo, Sorbitol, Inulin, I Mannitol, Chondroitinsulfat oder andere Mucopolysaccharidi Diese Verbindungen werden der Lösung in Konzentrationen » von 0,1 - 5% zugegeben.The solutions used according to the invention can also contain certain macromolecular substances to protect the urothelium, such as Albumin, polyvinylpyrrolidone, dextran, polyvinyl acetate, polyvinyl alcohol. Ethylene glycols with a middle j Molecular weight between 2,000 - 4,000, sorbitol, inulin, I. Mannitol, chondroitin sulfate or other mucopolysaccharides These compounds are added to the solution in concentrations of 0.1-5%.

Die Erfindung wird im folgenden anhand eines Beispieles näher erläutert:The invention is explained in more detail below using an example:

Beispiel 1example 1

Bei den In-vitro-Versuchen wurde nach dem Verfahren gearbeitet, das in wissenschaftliche Informationen ' Fresinius,Nephrologie Heft 2/79 veröffentlicht wurde. ;In the in-vitro tests, the procedure used in scientific information ' Fresinius, Nephrologie Heft 2/79 was published. ;

Die Behandlung der Harnsteine erfolgte mit Lösungen, ι die umgerechnet 0,75 g/^g Körpergewicht TricarboSLylsäurer oder eine andere litholytisch wirkende Carbonsäure und (1,2 -Diphenyläthylendinitrilo)-tetraessigsäure in 0,25 molarer Konzentration und Aluminium-Laktat in 0,25 molarer Konzentration enthielten. Zur Lockerung der Steinmatrix wurden zusätzlich 0,1 g/l Taurocholsäure hinzugefügt.The urinary stones were treated with solutions, ι the equivalent of 0.75 g / ^ g body weight TricarboSylic acid or another carboxylic acid with a litholytic effect and (1,2-diphenylethylenedinitrilo) tetraacetic acid in 0.25 molar concentration and aluminum lactate in 0.25 molar concentration. To loosen up an additional 0.1 g / l taurocholic acid was added to the stone matrix.

Bei allen Versuchen ließ sich eine sehr starke Reduzierung der Konkremente, teilweise bis zur völligen Auflösung, feststellen.In all of the tests, a very strong reduction in calculus was found, in some cases even complete Resolution, notice.

BAD ORIGINAL C0PYBATH ORIGINAL C0 PY

Claims (3)

Harnsteinauflösende Mittel. Patentansprüche.Urinary stone dissolving agents. Claims. 1.) Verwendung von litholytisch wirkenden Karbonsäuren oder Karbonsäurederivaten zur Pro- bzw. Metaphylaxe1.) Use of litholytically acting carboxylic acids or carboxylic acid derivatives for prophylaxis or metaphylaxis von Harnsteinen nach Patent (Patentanmeldungof urinary stones according to patent (patent application P 3o ^*6 58°·6) , dadurch gekennzeichnet, daß man die kalziumbindenden Verbindungen zusammen mit Kalzium komplexierenden und oxalatkomplexierenden Verbindungen einsetzt.P 3o ^ * 6 58 ° · 6), characterized in that the calcium-binding compounds together with calcium-complexing and oxalate-complexing compounds begins. 2.) Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß man als kalziumkomplexierende Verbindungen (D,L-2,3-Butylendinitrilo)-tetraessigsäure, (1,2-Diphenyläthylendinitrilo)-tetraessigsäure, (trans-Cyclopentylendinitrilo)-tetraessigsäure, 1,2,3-Tris (N,N-b i s(cafeoxymethyl)amino)-propan, (1-Phenyl- i2.) Use according to claim 1, characterized in that there is used as calcium complexing compounds (D, L-2,3-butylenedinitrilo) tetraacetic acid, (1,2-diphenylethylenedinitrilo) tetraacetic acid, (trans-Cyclopentylenedinitrilo) -tetraacetic acid, 1,2,3-tris (N, N-bis (cafeoxymethyl) amino) propane, (1-phenyl- i j äthylendinitrilo)-tetraessisäure, Triäthylentetramin- j hexaessigsäure, Tetraäthylenpentaamino-heptaesaigsäure, | trans-Diaminocyclohexan-Ν,Ν, N1N1-tetraessigsäure, gegebenenfalls in Form ihrer Alkali-, Magnesium-, Aluminium-, Eisen- oder Zinksalze Und als oxalatkomplexierende Spüllösungen wasserlösliche Salze von Aluminium, Eisen,Lanthan, Neodym, Niob, Yttrium, Ytterbium, Cer, Neptunium, Samarium, Gadolinium, Zink, Mangan, Lutetium, Magnesium oder Strontium einsetzt.j ethylenedinitrilo) tetraacic acid, triethylenetetramine j hexaacetic acid, tetraethylene pentaamino-heptaacetic acid, | trans-diaminocyclohexane-Ν, Ν, N 1 N 1 -tetraacetic acid, optionally in the form of its alkali, magnesium, aluminum, iron or zinc salts and, as oxalate-complexing rinsing solutions, water-soluble salts of aluminum, iron, lanthanum, neodymium, niobium, yttrium , Ytterbium, cerium, neptunium, samarium, gadolinium, zinc, manganese, lutetium, magnesium or strontium. 3.) Verwendung nach Anspruch 1 oder 2 dadurch gekennzeichnet daß man als oxalatkomplexierende Verbindungen Aluminium·1 Laktat, Aluminium-Citrat, Aluminium-Nitrat, Aluminium-Sulfat, Sisen-Citrat, Eisen-Kaliumcitrat, Eisen-Ammoniui citrat, Eisen-Glukonat, Eisen-Laktat, Eisensalze der3.) Use according to claim 1 or 2, characterized in that the oxalate complexing compounds aluminum · 1 lactate, aluminum citrate, aluminum nitrate, aluminum sulfate, iron citrate, iron potassium citrate, iron ammonium citrate, iron gluconate, Iron lactate, the iron salts - 2 BAD ORIGINAL- 2 ORIGINAL BATHROOMS COPYCOPY C I O f C IO f Glukose, Niob-Nitrat oder Lanthan-Nitrat einsetzt. Glucose, niobium nitrate or lanthanum nitrate is used. Verwendung nach Anspruch 1 - 3i dadurch gekennzeichnet, daß man zusätzlich Gallensäuren, Lezithin, Chrondroitineulfat und Katrium-Pyrophosphat als Kristallisationshemmer und i6*istalldesaggregatoren einsetzt. Use according to claims 1 to 3 , characterized in that bile acids, lecithin, chondroitin sulfate and sodium pyrophosphate are additionally used as crystallization inhibitors and general disaggregators . BAD ORIGINAL COPYBAD ORIGINAL COPY
DE19823213139 1980-12-11 1982-04-08 Compositions which dissolve urinary calculi Withdrawn DE3213139A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19823213139 DE3213139A1 (en) 1980-12-11 1982-04-08 Compositions which dissolve urinary calculi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19803046580 DE3046580A1 (en) 1980-12-11 1980-12-11 Prophylactic and curative treatment of urinary calculi - by admin. of organic acid, dye, metal oxide, etc.
DE19823213139 DE3213139A1 (en) 1980-12-11 1982-04-08 Compositions which dissolve urinary calculi

Publications (1)

Publication Number Publication Date
DE3213139A1 true DE3213139A1 (en) 1983-10-20

Family

ID=25789637

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19823213139 Withdrawn DE3213139A1 (en) 1980-12-11 1982-04-08 Compositions which dissolve urinary calculi

Country Status (1)

Country Link
DE (1) DE3213139A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304689A2 (en) * 1987-08-28 1989-03-01 LEOPOLD PHARMA GESELLSCHAFT m.b.H. Solution for use as a rinsing liquid in the destruction of the deposits extraneous to the body in human and animal tissues or in body cavities
JP2005507369A (en) * 2001-04-23 2005-03-17 アノーメッド インコーポレイティド Use of rare earth compounds for the prevention of kidney stone disease

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304689A2 (en) * 1987-08-28 1989-03-01 LEOPOLD PHARMA GESELLSCHAFT m.b.H. Solution for use as a rinsing liquid in the destruction of the deposits extraneous to the body in human and animal tissues or in body cavities
DE3728814A1 (en) * 1987-08-28 1989-03-30 Lentia Gmbh SOLUTION FOR USE AS A RINSING LIQUID IN THE DESTRUCTION OF NON-BODY DEPOSITS IN HUMAN AND ANIMAL TISSUES OR BODIES
EP0304689A3 (en) * 1987-08-28 1990-03-28 Leopold & Co Chem Pharm Solution for use as a rinsing liquid in the destruction of the deposits extraneous to the body in human and animal tissues or in body cavities
JP2005507369A (en) * 2001-04-23 2005-03-17 アノーメッド インコーポレイティド Use of rare earth compounds for the prevention of kidney stone disease
US7192609B2 (en) * 2001-04-23 2007-03-20 Shire International Licensing B.V. Use of rare earth compounds for the prevention of kidney stone disease

Similar Documents

Publication Publication Date Title
DE2555809A1 (en) SOLUTION FOR CLEANING SURFACES MADE OF COPPER AND ITS ALLOYS
DE2609039C3 (en) Process for making persistent sodium percarbonate
DE2240782A1 (en) METHOD FOR PRODUCING AN IRON SACCHARIDE COMPLEX
EP0256262A1 (en) Use of alpha-bisabolol in the stabilization of hydrogen peroxide
DE2514536A1 (en) METHOD OF REACTIVATING INTERFERON
DE1931451A1 (en) Cleaning agents for dental care
DE3345733A1 (en) STABILIZED SOLUTIONS OF HYDROXYLAMINE OR ITS SALTS IN WATER OR ALCOHOLS AND THE PRODUCTION THEREOF
DE3213139A1 (en) Compositions which dissolve urinary calculi
DE2631466C2 (en) Use of lanthanum, praseodymium and / or neodymium compounds as stabilizers for alkali percarbonates
DE266517C (en)
CH457386A (en) Process for the production of stannogluconic acid and its salts
DE1223396B (en) Process for the preparation of trisodium salts of the zinc complexes of diaethylenetriamine-N, N. N &#39;, N &#34;, N&#34; -pentaacetic acid and of triaethylenetetramine-N, N, N&#39;, N &#34;, N&#34; &#39;, N &#34;&#39; - hexaacetic acid
DE1618492B1 (en) Fructose production from sugar
DE836080C (en) Process for the production of a disinfectant containing rhodanic and 1-ascorbic acid, which can also be used for oral and dental care, using reductones and / or the cystine-cysteine redox system
DE1207048B (en) X-ray contrast media and process for their preparation
DE2428037C2 (en) Dentifrices such as toothpaste, tooth powder or the like
DE321616C (en) Process for the preservation of hydrogen peroxide solutions
DE1295750B (en) Impression material for dental purposes
DE1467259A1 (en) Process for the production of potassium magnesium fluoride
DE3127275A1 (en) &#34;MEDIUM-RESOLVING AGENTS&#34;
DE610185C (en) Process for stabilizing peroxide solutions
DE945989C (en) Soil improvers
DE589945C (en) Manufacture of base exchangers
DE954001C (en) Method for stabilizing an aqueous solution of an organic mercury diuretic containing the Hg-S group
DE348070C (en) Process for the preparation of metal compounds of sulfinides

Legal Events

Date Code Title Description
AF Is addition to no.

Ref country code: DE

Ref document number: 3046580

Format of ref document f/p: P

8141 Disposal/no request for examination